Substitute for form 1449A/PTO					Complete if Known				
INFORMATION DISCLOSURE A						Not yet known, 10 14540			
ST.	ATEMI	ENT BY	APPLICAN	T/	Filing Date	Herein-			
İ					First Name Inventor	Wolfgan	olfgang Guba		
	(Use sev	eral sheet	s if necessary)			626			
				ſ	Examiner Name		Kton		
Sheet 1	1				Attorney Docket Number	21553			
				U.S. PAT	ENT DOCUMENTS				
		U.	S. Patent Docu						
Examiner	Cite No.'	Kind Code			Name of Patentee or Applic	cant of	Date of Publication		
Initials'		Number		(if known)	Cited Document		Cited document		
100	A 1	5624	041	T	6 6		MM-DD-YY	YY	
- 30°	A1		5624941		Sanofi		04-29-1997		
-88	A2	3940			G.D. Searle & Co.		02-24-1976		
S	A3	5596	106		Eli Lily and Company		01-21-1997		
						-			
			· · · · · · · · · · · · · · · · · · ·						
			· · · · · · · · · · · · · · · · · · ·						
		l		-					
				ļ					
				1					
		 	-	<u> </u>					
		ļ							
<u> </u>				_					
				ļ					
	<u> </u>								
					ATENT DOCUMENTS				
. .	۵.	Foreign	n Patent Docum	nent			Date of Publication of Cited Document MM-DD-YYYY		
Examiner Initials'	Cite No.1	Office No.	Number	Kind Cod	Name of Patentee or				
initials				(if known)	Applicant of Cited Document				
X.	B1	WO0015609		Aventis Pharma S.A.	03-	03-23-2000			
<u> </u>	B2	WO0	164634		Aventis Pharma S.A.	09-	09-07-2001		
-887	B3	WO0228346		Aventis Pharma S.A.	04-11-2002				
æ3	B4	WO0164632		Aventis Pharma S.A.		07-2001	V		
883 30	B5	WO0164633				07-2001	1		
								 '	
88	B6	WUU	170700		Solvay		27-2001		
	<u> </u>				Pharmaceuticals B.V.			igspace	
圈	B7	WO0	132663		Sanofi-Synthelabo		10-2001	1	
XX.	B8	WO0046209		Sanofi-Synthelabo	08-	01-2000			
-RT	B9	WO9719063		Sanofi	05-	29-1997			
-883 -881	B10	EP65			Sanofi-Synthelabo		21-1995	1	
820	B11	EP656354		Sanofi		07-1995	1		
001			· - -					1	
88	B12	EP57			Sanofi		29-1993	1	
187	B13	WU9	602248		Eli Lilly and Compan	y 02-	01-1996	1	
Examiner		$\mathcal{L}_{\mathcal{C}}$	cun =	$P \subseteq$	tockton 2/17/3	1 5		-	
Signature	airial if anform				nce with MPFP 609. Draw line through distring if				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through ejiation if not in conformance and not considered. Include copy of this

^{*}EXAMINEN: Intuit in reference consistency, whether or not oscillate is in conformation with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.



Substitute for form 1449A/PTO				Complete if Known			
17	NFORMA'	TION	DISCLOSURE	Application Number	Not yet known /0/743 403		
S	STATEME!	NT B	Y APPLICANT	Filing Date	Herein- 12/22/03		
				First Name Inventor	Wolfgang Guba		
	(Use sever	ral shee	ets if necessary)	Group Art Unit			
				Examiner Name			
Sheet	2	Of	2	Attorney Docket Number	21553		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-	T²
	Cl	issue number(s), publisher, city and/or country where published PACHECO, M., ET AL., Aminoalkylindoles: Actions on	
*		Specific G-Protein-Linked Receptors, Journal of Pharmacology	
(30)		and Experimental Therapeutics, 1991, pp. 170-183, v. 257(1)	
	C2	CASIANO, F.M., ET AL., Putative Aminoalkylindoles (AAI)	
0~		Antagonists, Problems of Drug Dependence 1990: Proceedings	
40		of the 52 nd Annual Scientific Meeting The Committeee on	
		Problems of Drug Dependence, 1991, pp. 295-296, v. 105	
	C3	HOSOHATA, K., ET AL., AM630 is a Competitive	
38		Cannabinoid Receptor Antagonist in the Guinea Pig Brain, Life	
4	ļ	Sciences, 1997, pp. 115-118, v. 61(9)	
	C4	PERTWEE, R., ET AL., AM630, A Competitive Cannabinoid	
-OO		Receptor Antagonist, Life Sciences, 1995, pp. 1949-1955, v.	
480		56(23/24)	
	C5	FELDER, C.C., ET AL., LY320135, a Novel Cannabinoid CB1	
.Ozo		Receptor Antagonist, Unmasks Coupling of the CB1 Receptor	
280		to Stimulation of cAMP Accumulation, Journal of	
	ł	Pharmacology and Experimental Therapeutics, 1998, pp. 291-	
		297, v. 284(1)	
n0e	C6	KANYONYO, M. ET AL., 3-Alkyl-(5,5'-Diphenyl)	
<i>8</i> 8		Imidazolidinediones As New Cannabinoid Ligands, Bioorganic	
		& Medicinal Chemistry Letters, 1999, pp.2233-2236, v. 9	
oCO	C7	OOMS, F., ET AL., Exploration of the Pharmacophore of 3-	
-XX	Į	Alkyl-5-Arylimidazolidinediones as New CB ₁ Cannabinoid	
0		Receptor Ligands and Potential Antagonists: Synthesis,	
		Lipophilicity, Affinity, and Molecular Modeling, J. Med.	
		Chem., 2002, pp.1748-1756, v. 45(9)	
·			
-			
·			
	<u></u>		
Examiner Signature	Kam	DATE CONSIDERED 2 17/05	
Jignature J	10000	CONSIDERED TITLE	

*EXAMINER: Initial feerance considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached.

137401

5									
RAULUS IN	Substitute for form 1449A/PTO				Complete if Known				
IN	INFORMATION DISCLOSURE				Application Number	10/743,403			
ST ST	TATEM:	ENT BY	APPLICAN	TI [Filing Date	December 22, 2003			
					First Name Inventor	Wolfgan			
	(Use sev	veral sheets	if necessary)		Group Art Unit	1626			
					Examiner Name	Stockton			
Sheet	1	of	1		Attorney Docket Number	21553			
				U.S. PAT	ENT DOCUMENTS				
		U.S. Patent Document							
Examiner	Cite	Kind Code ²			Name of Patentee or Appl	icant of			
Initials'	No.'			(if known)	Cited Document		Cited document		
	 			т			MM-DD-YYY		
	 			 	-				
						· <u> </u>			
		-							
				 		 			
				 					
	 	 		 					
	 								
	ļ	ļ		ļ					
	ļ								
		i	<u>`</u>	<u> </u>					
	·	L	FO	REIGN P.	ATENT DOCUMENTS				
	I	Foreign	Patent Docum			Date	Date of Publication of T		
Examiner	Cite			Kind Code	Name of Patentee or	C	Cited Document		
Initials'	No.'	Office	Number 1	(if known)	Applicant of Cited Docume	ent M	nt MM-DD-YYYY		
<i>3</i> 83	B14	WO 01 58869		Bristol Myers Squibl					
782	B15	WO 00 46209		Sanofi-Synthelabo	08-10-2000				
"					·				
		_						\Box	
	i —							\vdash	
					-			$\vdash\vdash\vdash$	
							· · · · · · · · · · · · · · · · · · ·	 	
ļ	-		-					Щ	
ļ <u>.</u>	<u> </u>							igsquare	
			- Alley						

Examiner

Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through fitation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kinds of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.

142227